Avestin

An article appearing today the Urology Times E-News rang a warning bell about the use of the angiogenesis inhibitor bevacizumab (Avastin). The article warned that men with advanced prostate cancer may be at an increased risk of treatment-related death when bevacizumab is used in combination with other therapies. Senior author Shenhong Wu, MD, PhD, and [...]